The mycobiome-immune axis: The next frontier in pancreatic cancer.

Cancer Cell

Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA; Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY 10016, USA; Department of Surgery, NYU Grossman School of Medicine, New York, NY 10016, USA. Electronic address:

Published: February 2022

In this issue of Cancer Cell, Aftab et al. identify a pro-inflammatory cytokine, IL-33, that is released as a chemoattractant for type 2 immune cells in response to the intratumoral mycobiome. Depletion of fungi or deletion of IL-33 in cancer cells significantly decreases pancreatic ductal adenocarcinoma (PDAC) tumor progression and increases survival.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191147PMC
http://dx.doi.org/10.1016/j.ccell.2022.01.009DOI Listing

Publication Analysis

Top Keywords

mycobiome-immune axis
4
axis frontier
4
frontier pancreatic
4
pancreatic cancer
4
cancer issue
4
issue cancer
4
cancer cell
4
cell aftab
4
aftab et al
4
et al identify
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!